NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Ltd. Kck Sells 6,900 Shares

NeuroPace, Inc. (NASDAQ:NPCE) major shareholder Ltd. Kck sold 6,900 shares of NeuroPace stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $6.57, for a total transaction of $45,333.00. Following the completion of the sale, the insider now directly owns 5,510,957 shares in the company, valued at approximately $36,206,987.49. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Ltd. Kck also recently made the following trade(s):

• On Monday, October 14th, Ltd. Kck sold 4,031 shares of NeuroPace stock. The shares were sold at an average price of $6.54, for a total transaction of $26,362.74.
• On Friday, October 11th, Ltd. Kck sold 2,572 shares of NeuroPace stock. The stock was sold at an average price of $6.35, for a total value of $16,332.20.
• On Wednesday, October 9th, Ltd. Kck sold 3,123 shares of NeuroPace stock. The shares were sold at an average price of $6.10, for a total value of $19,050.30.
• On Monday, October 7th, Ltd. Kck sold 4,910 shares of NeuroPace stock. The shares were sold at an average price of $6.66, for a total value of $32,700.60.
• On Thursday, October 3rd, Ltd. Kck sold 3,318 shares of NeuroPace stock. The stock was sold at an average price of $6.97, for a total transaction of $23,126.46.

NeuroPace Trading Up 1.3 %

Shares of NPCE opened at $6.47 on Friday. NeuroPace, Inc. has a 1-year low of $5.73 and a 1-year high of $18.15. The company has a debt-to-equity ratio of 5.97, a current ratio of 6.37 and a quick ratio of 5.47. The firm has a 50 day simple moving average of $7.05 and a 200-day simple moving average of $8.41. The stock has a market cap of $186.13 million, a price-to-earnings ratio of -5.44 and a beta of 1.78.

NeuroPace (NASDAQ:NPCE) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.03. The company had revenue of $19.26 million during the quarter, compared to analysts’ expectations of $18.30 million. NeuroPace had a negative return on equity of 195.26% and a negative net margin of 41.63%. The business’s revenue for the quarter was up 16.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.36) earnings per share. Equities analysts forecast that NeuroPace, Inc. will post -1.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $18.00 target price on shares of NeuroPace in a research report on Wednesday, August 14th. Morgan Stanley dropped their price objective on NeuroPace from $9.50 to $8.00 and set an “equal weight” rating for the company in a research note on Monday, July 15th. Finally, Wells Fargo & Company reduced their price objective on NeuroPace from $20.00 to $15.00 and set an “overweight” rating for the company in a report on Wednesday, August 14th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, NeuroPace presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Financial Advocates Investment Management lifted its stake in shares of NeuroPace by 50.0% during the second quarter. Financial Advocates Investment Management now owns 15,000 shares of the company’s stock valued at $113,000 after buying an additional 5,000 shares during the period. XTX Topco Ltd raised its holdings in NeuroPace by 56.1% in the 2nd quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock valued at $182,000 after acquiring an additional 8,643 shares during the last quarter. Hillsdale Investment Management Inc. purchased a new position in shares of NeuroPace during the 1st quarter worth $155,000. Rhumbline Advisers acquired a new stake in shares of NeuroPace during the second quarter worth $111,000. Finally, Acadian Asset Management LLC grew its position in shares of NeuroPace by 46.0% in the second quarter. Acadian Asset Management LLC now owns 68,918 shares of the company’s stock valued at $520,000 after purchasing an additional 21,703 shares during the period. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.